Vertex Secures Reimbursed Casgevy Access in Scotland, Poised for Royalty Upside
Vertex Pharmaceuticals secured reimbursed access for sickle cell therapy Casgevy in Scotland in January, following coverage for roughly 90% of eligible U.S. patients. CRISPR Therapeutics reported 147 patient initiations and $116 million full-year Casgevy revenue in 2025, underscoring potential royalty and milestone revenue upside for Vertex.
1. Scotland Reimbursement Expansion
Vertex secured reimbursed access for its partner’s sickle cell gene therapy Casgevy in Scotland in January, marking the first inclusion of the drug in that market’s national reimbursement program.
2. U.S. and Global Coverage
Casgevy reimbursement now covers approximately 90% of eligible patients in the U.S. and has been adopted across several European and Middle Eastern markets, broadening patient reach.
3. Revenue and Royalty Implications
CRISPR Therapeutics reported $116 million in full-year Casgevy sales and 147 first cell collections in 2025, suggesting increasing milestones and royalty payments could bolster Vertex’s future revenue streams.